ERBB2 and neoplasm: For example, the FISH examination of HER2 and trastuzumab treatment were not covered by insurance in 2011, which led to HER2(2+) without a FISH exam in half of the population; therefore, we cannot define classical subtypes for every patient and cannot evaluate the effect of RDI among patients with HER2-positive or HER2-negative tumours.